Companies such as Xintong Pharmaceuticals, Renben Corporation, and Wolei Intelligence have applied for IPO on the Shanghai Stock Exchange.

Xi'an Newcom Pharmaceuticals Research Co., Ltd., Renben Co., Ltd., Hangzhou Vollly Intelligent Technology Co., Ltd., Jiangsu Gaokai Precision Fluid Technology Co., Ltd., Deep Blue Marine Technology Co., Ltd., and Suzhou Tongxin Medical Technology Co., Ltd. have their IPO applications accepted by the Shanghai Stock Exchange. According to the prospectus, Newcom Pharmaceuticals is a high-tech enterprise specializing in drug research and development for more than 20 years, focusing on drug development in major liver disease areas such as hepatitis B, metabolic dysfunction-related fatty liver disease, and liver cancer. The company is committed to developing innovative drugs with independent intellectual property rights, safety and effectiveness, and clinical value orientation, aiming to address the unmet clinical needs in the field of liver disease. As of the signing date of the prospectus, the company has 8 core products for treating liver diseases, including innovative drug product Tenofovir Disoproxil Tablets that has been approved for marketing, and two products MB07133 injection and Tenofovir Alafenamide Fumarate Tablets in seamless phase II/III pivotal clinical trials. One product XTYW001 has completed phase Ia clinical trial, one product XTYW007 has submitted an IND application, and three other liver disease products are in preclinical development stage. Renben Co., Ltd. is mainly engaged in the research, production, and sale of bearings and related products, being the largest comprehensive bearing manufacturing group in China with the widest range of products. The company's business covers more than 70 countries and regions globally, with nine production bases at home and abroad and nearly 20,000 employees. The company has the complete industrial chain research and manufacturing capabilities from bearing materials, components to finished products. Their bearing products include over 50,000 models and are widely used in automotive industry, light industry machinery, heavy machinery, and other important sectors of the national economy. Hangzhou Vollly Intelligence is primarily engaged in the research, production, sales, and service of intelligent testing equipment and smart manufacturing production lines, providing overall smart manufacturing solutions for emerging industries such as new energy vehicles and power semiconductors. It is a key national "small giant" enterprise in this field, offering intelligent testing and smart manufacturing solutions covering the full cycle of product development, verification, online testing, and automated manufacturing in automotive electronics industry. Jiangsu Gaokai Technology specializes in the research, production, and sales of key control components and related equipment in the field of precision fluid control. The company's product portfolio includes flow control series, dispensing packaging series, and precision sealing adhesive series, extending to more types of precision fluid control components and related equipment such as semiconductor vacuum system components. Their products are widely used in semiconductor, consumer electronics, automotive electronics, and new energy intelligent manufacturing fields. Deep Blue Marine's main business is the research, production, sales, and service of cable-controlled underwater vehicles, autonomous underwater vehicles, underwater gliders, automated profiling buoys, and underwater propulsion products, focusing on the field of "deep-sea technology." They provide products and professional solutions for marine safety, marine engineering, emergency rescue, hydroelectric power, marine scientific research, and marine tourism. The company has been a pioneer in the development of a full range of products in the field of cable-controlled underwater vehicles, with core technologies in underwater robot systems, underwater power and energy technologies, underwater robot control navigation and communication technologies, and advanced manufacturing technologies. Suzhou Tongxin Medical is a global medical device company that promotes the advancement and market development of late-stage heart failure treatment through breakthrough new technologies and solutions. In the Chinese market, their implanted full magnetic levitation left ventricular assist system CH-VAD has been approved for marketing by the National Medical Products Administration, becoming the first approved implanted full magnetic levitation artificial heart in China. Its iterative version CH-VADPlus is currently in the registration stage and is expected to be approved for marketing in China in early 2026. In the US market, their new generation implanted full magnetic levitation left ventricular assist system BrioVAD has received FDA approval for clinical trials, making it the first active implantable medical device from China to receive FDA approval for clinical trials. In the European market, the company has officially submitted an application for the pre-market clinical study of BrioLife, which is expected to start in the first half of 2026.